Merck & Company, Inc. Press Releases

MRK 
$58.36
*  
0.20
0.34%
Get MRK Alerts
*Delayed - data as of Jul. 26, 2016  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    MRK Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing

Merck Announces Fourth-Quarter 2016 Dividend
7/26/2016 12:50:00 PM - Business Wire
▲0.10 % Price Change since this news event. The Volume Ratio is 2.08.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)
7/25/2016 8:00:00 AM - Business Wire
▼-0.92 % Price Change since this news event. The Volume Ratio is 1.66.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...
7/22/2016 7:00:00 AM - Business Wire
▼-0.73 % Price Change since this news event. The Volume Ratio is 1.24.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical solution) for Cats and Dogs
7/21/2016 5:00:00 PM - Business Wire
▼-0.73 % Price Change since this news event. The Volume Ratio is 1.17.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab
7/21/2016 4:30:00 PM - Business Wire
▼-0.73 % Price Change since this news event. The Volume Ratio is 1.2.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Reorganization of electroCore management team as Frank Amato becomes CEO and founder JP Errico becomes Chief Science and Strategy Officer.
7/21/2016 6:00:00 AM - Business Wire
▼-0.15 % Price Change since this news event. The Volume Ratio is 1.08.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


This Deal Could Add Millions In Shareholder Value
7/19/2016 7:00:00 AM - AccessWire




Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company Vallée S.A.
7/1/2016 12:05:00 PM - Business Wire
▲0.78 % Price Change since this news event. The Volume Ratio is 0.77.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day








Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer
6/29/2016 7:00:00 AM - Business Wire
▲4.96 % Price Change since this news event. The Volume Ratio is 0.92.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
6/27/2016 6:00:00 AM - Business Wire
▲4.48 % Price Change since this news event. The Volume Ratio is 1.62.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29
6/24/2016 8:00:00 AM - Business Wire
▲4.07 % Price Change since this news event. The Volume Ratio is 1.63.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Roger Ulrich Joins Board of Remedy Pharmaceuticals
6/21/2016 10:00:00 AM - Business Wire


Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
6/20/2016 12:30:00 PM - Business Wire
▲3.35 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Systematic Review of 58 Publications of Real-World Use of GARDASIL® Presented at EUROGIN Congress
6/16/2016 8:00:00 AM - Business Wire
▲2.21 % Price Change since this news event. The Volume Ratio is 2.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
6/16/2016 6:45:00 AM - Business Wire
▲4.05 % Price Change since this news event. The Volume Ratio is 2.77.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ASM Microbe 2016
6/15/2016 8:30:00 AM - Business Wire
▲3.84 % Price Change since this news event. The Volume Ratio is 1.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


New Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma Symptoms in Children
6/13/2016 11:00:00 AM - PR Newswire
▲3.26 % Price Change since this news event. The Volume Ratio is 0.92.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus®
6/13/2016 10:30:00 AM - Business Wire
▲3.35 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
6/11/2016 11:00:00 AM - Business Wire
▲3.68 % Price Change since this news event. The Volume Ratio is 0.83.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day